Literature DB >> 26796979

Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma.

Tiffany Tang1, Zhengming Chen2, Pannee Praditsuktavorn3, Lay Poh Khoo4, Jia Ruan3, Soon Thye Lim4, Daryl Tan5, Colin Phipps5, Yuh Shan Lee5, Yeow Tee Goh5, William Hwang5, Miriam Tao4, Richard Quek4, Mohamad Farid4, Richard R Furman3, John P Leonard3, Peter Martin3.   

Abstract

INTRODUCTION: The role of surveillance imaging (SI) in patients with peripheral T-cell lymphoma (PTCL) in first complete remission (CR1) is unclear.
MATERIALS AND METHODS: Patients with PTCL were identified through prospectively maintained T-cell lymphoma databases from the National Cancer Centre Singapore/Singapore General Hospital and Weill-Cornell Medical College after institutional review board approval. Patients with leukemia or indolent, composite, and cutaneous lymphomas were excluded. The patients' medical records were retrospectively reviewed to determine the frequency and type of SI used. Of those with relapse, the method of relapse detection and data on symptoms, signs, and elevated lactate dehydrogenase LDH were extracted.
RESULTS: A total of 338 patients were included in the present study. In the first year after achieving CR1, patients had an average of 1.2 and a median of 1 SI performed (range, 0-4). In the second year after achieving CR1, they had an average of 0.78 and a median of 1 SI performed (range, 0-4). Of the 135 patients who achieved CR1, 61 (45%) developed a relapse. Relapses were detected before SI in 48 (84%), and 9 patients had relapses detected during routine SI. Of the 9 patients whose relapses were detected during planned SI, only 3 did not have any symptoms or signs suggestive of relapsed disease. Of these 3 patients, 2 had angioimmunoblastic T-cell lymphoma and 1 had natural killer/T-cell lymphoma.
CONCLUSION: Most PTCL relapses were detected before planned SI, and most patients had symptoms with relapse. Only 3 patients (5.2%) were completely asymptomatic at relapse, suggesting a limited utility of routine imaging for detecting PTCL relapses.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Imaging; Lymphoma; Peripheral; Surveillance; T cell

Mesh:

Year:  2015        PMID: 26796979     DOI: 10.1016/j.clml.2015.12.006

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  3 in total

1.  Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma.

Authors:  Ka-Won Kang; Se Ryeon Lee; Dae Sik Kim; Eun Sang Yu; Hwa Jung Sung; Seok Jin Kim; Chul Won Choi; Yong Park; Byung Soo Kim
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

2.  Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients.

Authors:  Hugo J A Adams; Thomas C Kwee
Journal:  Ann Hematol       Date:  2019-12-07       Impact factor: 3.673

3.  UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group.

Authors:  Philip Turton; Dima El-Sharkawi; Iain Lyburn; Bhupinder Sharma; Preethika Mahalingam; Suzanne D Turner; Fiona MacNeill; Laura Johnson; Stephen Hamilton; Cathy Burton; Nigel Mercer
Journal:  Br J Haematol       Date:  2020-11-22       Impact factor: 6.998

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.